Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
EntactogenLSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, DOx series, 2C-x series show less
βk-2C-B
β-keto-4-bromo-2,5-dimethoxyphenethylamine
βk-2C-B (beta-keto 2C-B) is a synthetic stimulant-psychedelic of the substituted cathinone and phenethylamine classes. It is a structural variant of 2C-B that requires far higher doses and lasts nearly twice as long. It blocks dopamine and norepinephrine reabsorption and activates serotonin receptors, producing stimulation alongside psychedelic perceptual shifts.
βk-2C-B (beta-keto 2C-B) is an emerging synthetic stimulant-psychedelic of the substituted cathinone and phenethylamine classes. It is the beta-keto structural analog of 2C-B, distinguished by higher effective doses and roughly double the duration. βk-2C-B is a presumed norepinephrine–dopamine reuptake inhibitor and serotonin 2A receptor agonist, though no receptor binding data have been published.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
EntactogenLSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, DOx series, 2C-x series show less
First discussed on an internet forum in December 2007, βk-2C-B attracted little attention until research chemical vendors began selling it around 2013–2014 as a legal substitute for 2C-B. The first scientific characterization came in 2015.[1] It remains unscheduled in most jurisdictions and circulates in small quantities on research chemical markets.
Subjective effects include geometric visual patterns, physical euphoria, empathogenic warmth, stimulation, and pronounced body load. The experience blends a sustained stimulant foundation with psychedelic perceptual shifts and social openness — closer in character to mescaline-type compounds than to psilocybin or LSD.[2] Nausea, anxiety, and heavy body load are common, particularly at higher doses.[3]
βk-2C-B is not considered habit-forming, but the toxic and lethal doses are unknown. It combines cardiovascular stimulation from the cathinone component with serotonergic psychedelic load — one unverified report describes cardiac arrest following use,[3] and smoking it produces at least 12 combustion products of unknown toxicity.[4] No clinical study exists — what is known comes entirely from analytical chemistry and community self-reports.
History[edit]
History
Discovery
βk-2C-B first appeared in public discussion in December 2007, when a user on Bluelight.org opened a thread on the compound.[2] Activity was minimal for years. The first formal scientific characterization came in 2015, when Power et al. purchased a commercial sample and identified it using NMR, GC-MS, LC-HRMS, and X-ray crystallography.[1] An earlier attribution to Glennon and colleagues in 2004 has not been verified.citation needed
Market emergence and forensic detection
By 2013–2014, research chemical vendors were marketing βk-2C-B as a legal replacement for 2C-B. Italian forensic laboratories confirmed it in seized materials during 2013–2015,[5] and the U.R.I.To.N. Consortium confirmed its identity by additional methods.[6] A separate study found at least 12 toxic combustion products when the compound was heated in a simulated pipe.[4]
Scheduling and current status
Germany controlled βk-2C-B in November 2016, the UK's blanket psychoactive substance law covered it from May 2016, and Sweden classified it as a narcotic in April 2019.[7] As of 2026, it remains unscheduled in most countries. No clinical trial has been registered and no pharmacological study has been published.
The name βk-2C-B follows research chemical naming conventions: the βk prefix denotes the beta-keto modification, and 2C-B identifies the parent molecule in Shulgin's 2C-x series. The compound also appears as bk-2C-B and beta-keto 2C-B. Its marketing as a legal substitute for 2C-B shaped early perception, though the experience differs substantially in duration, dosage, and stimulant character.
Chemistry[edit]
Chemistry
Structure
βk-2C-B belongs to two overlapping chemical families: the substituted phenethylamines (specifically the 2C-x series) and the substituted cathinones.[1][8] It is the beta-keto structural analog of 2C-B — the same aromatic ring carrying two methoxy groups and a bromine, but with a carbonyl oxygen added to the side chain that converts the phenethylamine structure into a cathinone.[1] Its molecular formula is C₁₀H₁₂BrNO₃ (274.11 g/mol).
The added carbonyl group reduces the compound's fat-solubility compared to 2C-B.[8] This is likely why βk-2C-B requires roughly 4–10 times the dose of 2C-B to produce effects — it crosses into the brain more slowly. Commercially available material is a mixed hydrochloride/hydrobromide salt,[1] and heating it generates at least 12 breakdown products of uncharacterized toxicity.[4]
Pharmacology[edit]
Pharmacology
Mechanism of action
No receptor binding data have been published for βk-2C-B. The bromine and methoxy groups on its aromatic ring — the same pattern found in 2C-B — are associated with serotonin receptor activation,[9][10] the likely basis for the psychedelic effects. The cathinone backbone predicts blockade of dopamine and norepinephrine reabsorption, producing stimulation.[8][11][12] Neither mechanism has been confirmed in a laboratory study.
Pharmacokinetics
No human pharmacokinetic data exist. The beta-keto group reduces fat-solubility, slowing how fast βk-2C-B enters the brain compared to 2C-B[8] — probably explaining the much higher effective dose. Community reports place total duration at 8–12 hours,[2] roughly double that of 2C-B.[13][14] CYP2D6 involvement in metabolism is possible by analogy to related compounds,[15] but this is unconfirmed.
Neuroscience[edit]
Neuroscience
No neuroimaging or neuropharmacological studies have been conducted with βk-2C-B. The neural mechanisms below are extrapolated from its predicted dual pharmacology.
Where it acts
If βk-2C-B activates serotonin receptors as predicted, the expected neural effect is the classic psychedelic signature: disrupted internal narrative, reduced filtering of sensory information, and increased mental noise. At the same time, the cathinone component is predicted to engage reward and arousal circuits through dopamine and norepinephrine — adding stimulation and euphoria through a separate pathway.
Why it matters
The simultaneous engagement of serotonergic psychedelic and catecholaminergic stimulant circuits is pharmacologically unusual. Psychedelics typically quiet goal-directed thinking — stimulants sharpen it. Community reports of empathogenic warmth suggest emotional processing circuits may also be involved, though the mechanism is unknown.
- Does βk-2C-B produce functional serotonin receptor agonism in vivo, or are its psychedelic effects secondary to catecholaminergic mechanisms[10]?
- What explains the 8–12 hour duration — slower brain equilibration, active metabolites, or sustained transporter effects?
- Community reports describe qualitatively different experiences at moderate versus high doses,[3] suggesting distinct pharmacological mechanisms may engage at different dose levels.
Subjective Effects[edit]
The βk-2C-B experience is built on a sustained stimulant foundation overlaid with psychedelic perceptual shifts and social warmth. Physical stimulation runs through the entire arc — more persistent than in most serotonergic psychedelics. Set, setting, and dose exert strong influence; moderate and high doses can feel qualitatively different from each other.[3]
Community reports position it between 2C-B and entactogen-type cathinones, with a perceptual character closer to mescaline-containing cacti than to psilocybin.[2] The stimulant undertone is absent in those comparisons. It is not a lighter version of 2C-B — it is a longer, heavier, more stimulating compound in a distinct experiential category.
First discussed on internet forums in December 2007, βk-2C-B remained obscure until research chemical vendors began marketing it around 2013–2014 as a legal alternative to 2C-B. The first peer-reviewed work — analytical characterization by Power et al. — appeared in 2015,[1] but no pharmacological study has followed. It remains unscheduled in most jurisdictions, circulating in small quantities on research chemical markets.
Subjective effects include geometric visual patterns, physical euphoria, empathogenic warmth, stimulation, and body load. The experience blends a sustained stimulant foundation with psychedelic perceptual shifts and social openness — closer in character to mescaline-class compounds than to psilocybin or LSD.[2] Pronounced body load, nausea, and anxiety at higher doses are common unsought effects.[3]
βk-2C-B is not considered habit-forming, but the toxic dose and lethal dose are unknown — one unverified report describes sudden cardiac arrest following use.[3] Heating the compound produces at least 12 pyrolysis products of uncharacterized toxicity, making smoking the highest-risk route;[4] the cathinone scaffold adds cardiovascular stimulation on top of 2C-B-type serotonergic load. No clinical trial, receptor binding study, or pharmacokinetic assessment has been published — the current understanding rests entirely on analytical chemistry, structural inference, and community self-reports.
History[edit]
History
Discovery
βk-2C-B first appeared in public discussion in December 2007, when a user on the Bluelight.org forum opened a thread on the compound — activity was minimal, with roughly 20 posts over the following six years.[2] Several secondary sources attribute an earlier description to Glennon and colleagues in 2004, but this citation has not been verified through database searches.citation needed The first formal scientific characterization came in 2015, when Power et al. test-purchased a commercial sample and identified it using NMR, GC-MS, LC-HRMS, and X-ray crystallography.[1]
Market emergence and forensic detection
βk-2C-B began appearing on research chemical vendor sites around 2013–2014, marketed as a legal replacement for 2C-B, which had been scheduled in most major jurisdictions. Italian forensic laboratories documented the compound in seized materials during 2013–2015,[5] and the U.R.I.To.N. Consortium confirmed its identity using LC-MS/MS and NMR.[6] Texter et al. conducted the only study addressing the smoking route, identifying 12 pyrolysis products when the compound was heated in a simulated glass pipe.[4]
Scheduling and current status
Regulatory responses followed the compound's market emergence. Germany controlled it under the NpSG in November 2016; the United Kingdom's Psychoactive Substances Act provided blanket coverage from May 2016; Sweden classified it as a narcotic in April 2019.[7] As of 2026, no clinical trial has been registered and no formal pharmacological study has been published.
The name βk-2C-B follows systematic research chemical naming conventions: "βk" denotes the beta-keto modification of the parent compound's side chain, and "2C-B" identifies the parent molecule in Shulgin's 2C-x series — the "2C" referring to two carbon atoms in the phenethylamine backbone. The compound is sometimes listed under alternative designations including bk-2C-B and beta-keto 2C-B. Its positioning as a "legal 2C-B" shaped early market perception, though the experience differs substantially from its parent compound in duration, dosage, and stimulant character.
Chemistry[edit]
Chemistry
Structure
βk-2C-B sits at the intersection of two chemical families: the substituted phenethylamines (specifically the 2C-x series) and the substituted cathinones. It is formally the beta-keto structural analog of 2C-B — generated by oxidizing the beta-carbon of 2C-B's side chain to a carbonyl group, converting the aminoethyl chain into an aminomethyl ketone.[1][8]
The aromatic ring carries two methoxy groups at positions 2 and 5 and a bromine at position 4 — the same substitution pattern found in 2C-B and the DOB series. The side chain distinguishes βk-2C-B: an aminomethyl group bonded to a carbonyl carbon attached directly to the ring, where 2C-B has a two-carbon aminoethyl chain without a carbonyl.[1]
| Molecular formula | C₁₀H₁₂BrNO₃ |
| Molecular weight | 274.11 g/mol |
Stereochemistry
βk-2C-B lacks a chirality center. The alpha-carbon is part of the carbonyl system, making the aminomethyl group achiral. The compound exists as a single form with no enantiomers.
Key structural features
The beta-keto group reduces lipophilicity relative to 2C-B — a property common to cathinones that typically reduces blood-brain barrier penetration.[8] This likely explains why βk-2C-B requires roughly 4–10× the dose of 2C-B to produce psychoactive effects. Commercially available material has been identified as a mixed hydrochloride/hydrobromide salt, consistent with synthesis via the hexamethylenetetramine route.[1]
Analytical notes
GC-MS analysis can produce artifact peaks from thermal decomposition in the injection port; LC-MS is the preferred identification method.[1] Pyrolysis at higher temperatures generates at least 12 degradation products, all confirmed by independent synthesis.[4]
Pharmacology[edit]
Pharmacology
Mechanism of action
No receptor binding or functional assay data have been published for βk-2C-B. Its pharmacological profile is inferred entirely from its hybrid structure, which predicts two distinct mechanisms.
The 4-bromo-2,5-dimethoxyphenyl ring — the same aromatic scaffold found in 2C-B — is the structural basis for serotonergic psychedelic activity. This substitution pattern is associated with 5-HT₂A receptor agonism, and the 2,5-dimethoxy motif contributes to potency beyond what receptor affinity alone predicts.[9] However, phenethylamine psychedelics of the 2C-x class show lower intrinsic activity at 5-HT₂A than their amphetamine counterparts,[10] and the additional beta-keto modification may reduce this further. Whether βk-2C-B retains meaningful 5-HT₂A agonism remains an open question.
The beta-keto carbonyl defines the cathinone scaffold, a class that primarily functions through monoamine reuptake inhibitor — blocking the reabsorption of norepinephrine and dopamine, with cathinones generally showing greater dopaminergic than serotonergic selectivity.[8][11] Cathinones act as central nervous system stimulants primarily through catecholamine release and reuptake blockade.[12] This component likely accounts for βk-2C-B's pronounced stimulant character, while the reported visual and perceptual effects suggest some degree of serotonin receptor engagement.
Pharmacokinetics
No human or animal pharmacokinetic studies exist for βk-2C-B. Peak plasma concentration, half-life, bioavailability, and clearance are all unknown.
The reduced lipophilicity from the beta-keto group likely slows blood-brain barrier penetration compared to 2C-B,[8] probably accounting for the 4–10× higher effective dose. For reference, oral 2C-B reaches peak salivary concentration approximately 1 hour after ingestion,[13] with effects largely resolving within 6 hours.[14] Both studies documented increases in blood pressure and heart rate.[13][14]
Community reports place βk-2C-B's total duration at 8–12 hours[2] — roughly double that of 2C-B. The mechanism behind this extended duration is unknown; candidates include slower CNS penetration, different metabolic fate, or sustained monoamine transporter effects.
No metabolic data exist. Beta-keto reduction to a corresponding amino alcohol is a common cathinone metabolic pathway;[12] this could theoretically generate 2C-B or a related metabolite, though this remains unconfirmed. CYP2D6 involvement is plausible by analogy to the related compound 2C-B-FLY,[15] but undemonstrated.
Neuroscience[edit]
Neuroscience
No neuroimaging or neuropharmacological studies have been conducted with βk-2C-B. The neural mechanisms below are extrapolated from its predicted dual pharmacology.
Where it acts
If βk-2C-B retains meaningful 5-HT₂A agonism, the expected neural signature includes disruption of default mode network integrity, reduced thalamocortical filtering, and elevated neural entropy — the canonical psychedelic profile mediated by serotonin receptors on cortical pyramidal neurons. Simultaneously, the cathinone scaffold's predicted dopamine and norepinephrine reuptake inhibitor would engage the brain's reward and arousal circuits, producing stimulation and euphoria through pathways distinct from the psychedelic component.
Why it matters
The simultaneous engagement of serotonergic psychedelic and catecholaminergic stimulant circuits is pharmacologically unusual. The REBUS framework proposes that psychedelics flatten prior beliefs by increasing neural entropy — but concurrent stimulant activity may counteract this by enhancing focused, goal-directed processing, potentially producing a more directed psychedelic state than compounds acting purely through 5-HT₂A agonism. Community reports of empathogenic warmth suggest possible modulation of emotional processing circuits, though the mechanism is unknown.
- Does βk-2C-B produce functional 5-HT₂A agonism in vivo, or are its psychedelic effects secondary to catecholaminergic mechanisms[10]?
- What explains the 8–12 hour duration — slower CNS equilibration, active metabolites, or sustained transporter occupancy?
- Community reports describe qualitatively different experiences at moderate versus high doses,[3] raising the possibility of a threshold effect where distinct pharmacological mechanisms engage at different dose levels.
Subjective Effects[edit]
The βk-2C-B experience is defined by a sustained stimulant foundation overlaid with psychedelic perceptual shifts and empathogenic warmth. Set, setting, and dose exert strong influence — reports describe markedly different experiences at moderate versus high doses, suggesting the engagement of distinct pharmacological mechanisms may shift across the dose range.[3] The physical stimulation is more prominent and persistent than in most serotonergic psychedelics, coloring the entire arc.
Comparisons in community reports position βk-2C-B between 2C-B and the substituted cathinone entactogens, with a perceptual character closer to mescaline-containing cacti than to psilocybin or ayahuasca, plus a stimulant undertone absent in those comparisons.[2]
Effect Grid
At 80–100 mg, the full psychedelic-stimulant hybrid character emerges. Visual geometry becomes clear — open- and closed-eye patterns, color enhancement, and visual drifting are prominent. Cognitive euphoria and thought acceleration are pronounced, alongside empathogenic effects including emotional enhancement, sociability enhancement, and social connection.
Stimulation is the dominant physical feature, accompanied by pupil dilation, wakefulness, and appetite suppression. Nausea is common during the come-up phase and may last 30–60 minutes. Bruxism, muscle tension, and excessive sweating may occur. Cardiovascular stimulation is expected.
Time alteration is noticeable. Duration is typically 8–10 hours, with insomnia persisting well beyond the subjective offset. Full functional recovery requires at least 12 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Perspective distortion · Symmetrical texture repetition · Depth perception distortion · Tracers · Visual breathing · Environmental patterning · Light sensitivity · Sound sensitivity · Touch enhancement · Visual diffraction · After-images · Visual morphing · Visual haze / noise · Auditory distortion · Auditory enhancement · Peripheral vision distortion · Spatial disorientation · Visual melting · Auditory misinterpretation · Synesthesia · Proprioceptive distortion · Visual acuity enhancement · Object transformations · Object activation · Internal hallucinations · Environmental orbism / cubism · External hallucinations
Tracers · Visual breathing · Environmental patterning · Light sensitivity · Sound sensitivity · Touch enhancement · Visual diffraction · After-images · Visual morphing · Visual haze / noise · Auditory distortion · Auditory enhancement · Peripheral vision distortion · Spatial disorientation · Visual melting · Auditory misinterpretation · Synesthesia · Proprioceptive distortion · Visual acuity enhancement · Object transformations · Object activation · Internal hallucinations · Environmental orbism / cubism · External hallucinations
Appetite suppression · Dry mouth · Heart rate perception changes · Body high · Spontaneous body sensations · Excessive sweating · Restlessness · Insomnia · Dehydration sensation · Tactile euphoria · Tingling / electric sensations · Nausea · Muscle tension · Bruxism · Laughter fits · Vibrations / buzzing · Bodily lightness · Sexual arousal enhancement · Dizziness
Spontaneous body sensations · Excessive sweating · Restlessness · Insomnia · Dehydration sensation · Tactile euphoria · Tingling / electric sensations · Nausea · Muscle tension · Bruxism · Laughter fits · Vibrations / buzzing · Bodily lightness · Sexual arousal enhancement · Dizziness
Conceptual thinking · Cognitive euphoria · Pattern recognition enhancement · Introspection enhancement · Openness enhancement · Cognitive flexibility · Thought acceleration · Thought connectivity · Creativity enhancement · Memory suppression · Thought loops · Humor enhancement · Multiple thought streams · Cognitive impairment · Increased nature relatedness · Analysis enhancement · Focus enhancement · Information processing enhancement · Motivation enhancement · Thought disorganization · Confusion · Delusions
Introspection enhancement · Openness enhancement · Cognitive flexibility · Thought acceleration · Thought connectivity · Creativity enhancement · Memory suppression · Thought loops · Humor enhancement · Multiple thought streams · Cognitive impairment · Increased nature relatedness · Analysis enhancement · Focus enhancement · Information processing enhancement · Motivation enhancement · Thought disorganization · Confusion
Anxiety · Simultaneous emotions · Anxiety suppression · Catharsis · Dysphoria
Dysphoria
Sociability enhancement · Communication enhancement · Derealization · Depersonalization · Boundary dissolution · Ego dissolution
Boundary dissolution · Ego dissolution
Timeline
Initial stimulation and body sensations emerge; nausea may begin. Minimal psychedelic effects — awareness of altered state without prominent perceptual changes. Onset is notably variable across individuals.
Escalating visual and empathogenic effects; body load peaks with nausea and cardiovascular stimulation. Stimulation intensifies alongside emerging color enhancement and visual drifting.
Full psychedelic-stimulant experience — visual geometry, color enhancement, cognitive euphoria, empathogenic warmth, and time alteration at maximum intensity. Pronounced stimulation and wakefulness.
Gradual reduction in visual and psychedelic effects. Stimulation persists longer than perceptual effects. Mood may shift toward fatigue or mild dysphoria.
Residual stimulation, mild mood elevation or fatigue depending on dose. Sleep remains difficult for several hours. Appetite gradually returns.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No controlled toxicological data exist — the toxic and lethal doses are unknown. One unverified community report describes sudden cardiac arrest following use,[3]safety citation needed and a second describes hospitalization after combining βk-2C-B with amphetamine and MDMA during sleep deprivation — too many variables to attribute the outcome clearly.[3] Of 25 community reports on Erowid, 8 are classified as difficult experiences and 3 as disasters.[3]
Cardiovascular risk
The cathinone scaffold raises heart rate and blood pressure. In severe cases, cathinones produce dangerous overheating, muscle breakdown, and organ damage.[12]
βk-2C-B combines cathinone-type cardiovascular stimulation with serotonergic psychedelic activity — a theoretical additive burden that has not been measured.[13][14]
Pyrolysis hazards
Heating βk-2C-B produces at least 12 pyrolysis products, none of which have been toxicologically characterized.[4] Inhaling vaporized or smoked βk-2C-B exposes the user to combustion products of unknown toxicity. Oral administration is the only route with any documented experience base.
Combining βk-2C-B with other drugs substantially increases the risk of serious adverse effects.[16]
Psychological risks
Phenethylamine psychedelics can trigger panic, severe anxiety, and transient psychosis, particularly at higher doses.[8][17] Persistent visual disturbances after the experience — patterns and after-images that remain for weeks or months — are documented across the psychedelic class.[8]
The cathinone component may add extra risk of paranoia and agitation beyond what serotonergic psychedelics produce alone.[12] Community reports suggest most difficult experiences occur above approximately 130–150 mg.[3]
Tolerance and dependence
βk-2C-B is not considered habit-forming. Tolerance builds rapidly — near-complete after a single dose — through serotonin downregulation, a mechanism documented across serotonergic psychedelics.[18] Cross-tolerance with other psychedelics exists,[18] and community consensus places full reset at around 7 days.[2]
Physical dependence and withdrawal have not been reported. Rapid tolerance development prevents the escalating use patterns that typically drive dependence.[12]
Drug Interactions
No published interaction data exist for βk-2C-B. All interactions below are inferred from its dual pharmacological class.
- MAOIs (phenelzine, tranylcypromine, moclobemide, selegiline, linezolid): Combined serotonergic activity can trigger serotonin syndrome — a life-threatening overheating and seizure response.[19][16]
- SSRIs and SNRIs: May reduce the psychedelic effect while adding to serotonin overload risk.[19]
- Other serotonergic psychedelics and MDMA: Additive serotonergic burden. At least one hospitalization involved combined βk-2C-B and MDMA use.[3]
- Stimulants (amphetamines, cocaine, methylphenidate): Additive risk of raised heart rate and blood pressure from combined catecholaminergic effects.[3]
- Cannabis: May intensify psychotic symptoms and panic. No βk-2C-B-specific data exist.
- Lithium: Reported to lower seizure threshold when combined with psychedelics. citation needed
- Tricyclic antidepressants: Potential for combined cardiovascular effects via noradrenergic mechanisms. inferred
Contraindications
8 knownNo substance-specific contraindication data exist. The following are inferred from βk-2C-B's dual pharmacological class.
Absolute (class-inferred):
- Concurrent MAOI use: Risk of serotonin syndrome.[19]
- Known heart condition (high blood pressure, irregular heartbeat, coronary artery disease, heart failure): Combined cardiovascular stimulation from both cathinone and serotonergic activity represents significant unquantified risk. One unverified report describes cardiac arrest.[3] safety citation needed
- Personal or family history of psychotic disorders: Phenethylamine psychedelics can precipitate acute psychosis.[8]
Relative (class-inferred):
- Seizure disorders: Both cathinones and serotonergic psychedelics are associated with lowered seizure threshold.[12]
- Liver impairment: If CYP2D6 mediates metabolism (by analogy to 2C-B-FLY[15]), altered liver function could affect clearance. This is speculative.
- Pregnancy and breastfeeding: No reproductive toxicity data exist. Contraindicated by precautionary principle.
- Concurrent serotonergic medication (SSRIs, SNRIs, triptans, tramadol): Risk of serotonin syndrome and unpredictable interactions.[19]
- CYP2D6 poor metabolizer status: Could prolong or intensify effects if CYP2D6 mediates metabolism. Speculative. inferred
Harm Reduction[edit]
Forms & Identification
βk-2C-B is sold as an unregulated powder with no quality controls. The effective dose range (80–150 mg) demands a milligram-precision scale — a standard kitchen scale is not accurate enough. Reagent testing confirms the presence of a phenethylamine-type compound but cannot distinguish βk-2C-B from structurally similar substances.
Guidelines
- Test every batch with reagent kits before use. A milligram-precision scale is mandatory at this dose range.
- Start at the low end of the reported range and wait at least 2–3 hours before considering redosing — onset can be slow and unpredictable.
- Clear the entire day. The 8–12 hour duration plus residual stimulation extends well beyond the primary effects.
- Eat a light meal 2–3 hours before. Hydrate steadily but do not overhydrate.
- Have a sober sitter present, particularly above 130 mg.
- Do not smoke or vaporize this compound. Heating produces toxic pyrolysis products.[4]
- Do not redose to chase effects — the slow onset and long duration make compounding doses a significant risk.
Set & Setting
The 8–12 hour duration makes environment planning essential — a comfortable, familiar space with no obligations for the full day is the minimum. The stimulant component means sleep will not be possible for many hours after ingestion. A trusted, sober companion is strongly recommended, especially at doses approaching or exceeding 130 mg.
Aftercare & integration. The extended duration and stimulant component often leave users physically drained. Prioritize sleep, hydration, and nutrition in the 24–48 hours following use. Residual stimulation may make falling asleep difficult — avoid caffeine and allow the body to wind down naturally.
If the experience was psychologically intense or distressing, journaling and conversation with a trusted person can help process what emerged. Professional psychedelic integration support is appropriate if distressing material persists beyond a few days.
Recovery & Support
βk-2C-B is not considered physically addictive, and compulsive use patterns are rare due to rapid tolerance. If use has become a coping mechanism or is causing disruption in daily life, this reflects a pattern worth examining regardless of the substance's pharmacological dependence profile. Peer support communities, harm reduction organizations, and therapists experienced with substance use can provide confidential, non-judgmental support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, racing or irregular heartbeat, seizure, loss of consciousness, body temperature hot to the touch, severe confusion, or self-harm behavior all require immediate help. Intense anxiety or a difficult psychological experience is not the same as a medical emergency — reassurance, a calm environment, and patient companionship are usually sufficient.
Immediate steps:
- 1. Move the person to a safe, quiet space.
- 2. Call emergency services if chest pain, seizure, loss of consciousness, or dangerously high body temperature are present.
- 3. Do not restrain the person unless they are in immediate physical danger.
- 4. If the person is unconscious but breathing, place them in the recovery position.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (βk-2C-B / beta-keto 2C-B), approximate dose, time of ingestion, and current symptoms. Be honest about what was taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
βk-2C-B is not internationally scheduled under United Nations conventions. Control varies by jurisdiction — some countries have scheduled it specifically, others rely on blanket psychoactive substance laws, and others have not addressed it at all.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled (federal) | Not explicitly listed in DEA Schedules. The Federal Analogue Act may apply if βk-2C-B is deemed substantially similar to 2C-B (Schedule I), making production, sale, or possession with intent for human consumption a potential federal offense. Interpretation is case-dependent.[7] |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Illegal to produce, supply, or import under blanket psychoactive substance legislation, effective May 26, 2016. Personal possession is not an offense under this Act.[7] |
| Germany | Controlled (NpSG) | Covered under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act), effective November 26, 2016.[7] |
| Switzerland | Controlled (named substance) | Listed as a named substance under Verzeichnis E of Swiss narcotics legislation.[7] |
| Sweden | Narcotic | Classified as a narcotic substance as of April 5, 2019.[7] |
| Canada | Reported Schedule III (CDSA) | Reported as Schedule III under the Controlled Drugs and Substances Act as of October 2016. Canada Gazette Order SOR/2016-73 added 2C-phenethylamine derivatives to Schedule III;[20] however, βk-2C-B is not explicitly named in that Order. Its coverage may depend on class language or a separate order. citation needed |
| Australia | Unconfirmed | Not specifically scheduled under federal or state legislation at the time of research. The cathinone and phenethylamine analogue provisions may apply. citation needed |
Analog and structural considerations
βk-2C-B's hybrid structure complicates its classification. In jurisdictions with structural analog provisions — such as the US Federal Analogue Act — it could be prosecuted as an analog of 2C-B based on the shared aromatic scaffold, or as an analog of scheduled cathinones based on the beta-keto backbone. Neither interpretation has been tested in court for this compound.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No controlled toxicological data exist for βk-2C-B. The toxic dose, lethal dose, and therapeutic index are unknown. No animal toxicity studies have been published.
Acute toxicity
One unverified community report on Erowid describes sudden cardiac arrest following βk-2C-B use.[3] The dose, co-ingestants, medical history, and outcome are unconfirmed in the peer-reviewed literature. safety citation needed
A second report describes hospitalization after combined use of βk-2C-B with amphetamine and MDMA during sleep deprivation — a polydrug context that prevents clear attribution.[3] Of 25 experience reports on Erowid, 8 are classified as "difficult experiences" and 3 as "train wrecks and disasters".[3]
Cardiovascular risk
The cathinone scaffold predicts cardiovascular stimulation. Cathinones as a class produce increased heart rate, elevated blood pressure, and in severe cases, dangerous overheating, muscle breakdown, and organ damage.[12] The parent compound 2C-B raises blood pressure and heart rate at standard doses.[13][14]
βk-2C-B combines both cathinone-type and serotonergic cardiovascular stimulation — a theoretical additive burden that has not been measured.
Pyrolysis hazards
Heating βk-2C-B produces at least 12 pyrolysis products, none of which have been toxicologically characterized.[4] Inhalation of vaporized or smoked βk-2C-B exposes users to combustion products of unknown toxicity. Oral administration is the only route with any documented experience base.
Polydrug use with designer drugs substantially increases the risk of severe adverse effects.[16]
Psychological risks
No substance-specific psychological risk data exist. The following risks are documented for the phenethylamine psychedelic class:
- Acute psychotic reactions: Phenethylamine psychedelics can trigger transient psychosis, panic, and severe anxiety, particularly at higher doses or in predisposed individuals.[17][18]
- Hallucinogen persisting perception disorder (HPPD): Persistent visual disturbances following psychedelic use are documented across the class.[17]
- Paranoia and agitation: The cathinone component may add risk of paranoia and agitation beyond what serotonergic psychedelics alone produce.[12]
Community reports suggest dose strongly moderates psychological risk, with more distressing experiences reported above approximately 130–150 mg.[3]
Tolerance and dependence
βk-2C-B is not considered habit-forming. No cases of dependence or physical withdrawal have been reported.
Tolerance builds rapidly — near-complete after a single dose — via 5-HT₂A downregulation, a mechanism documented across serotonergic psychedelics.[19] Cross-tolerance exists within the psychedelic class.[19] Community consensus places tolerance half-life at approximately 3 days, with full reset at 7 days.[2]
Dependence potential is low. While cathinones possess reinforcing properties in animal studies,[12] rapid tolerance development prevents the escalating use patterns that typically drive dependence. The psychedelic component's self-limiting nature further reduces compulsive redosing risk.
Drug Interactions
No published interaction data exist for βk-2C-B. All interactions below are inferred from the compound's dual pharmacological class.
- MAOIs (phenelzine, tranylcypromine, moclobemide, selegiline, linezolid): Risk of serotonin syndrome from combined serotonergic activity.[20][16]
- SSRIs and SNRIs: May blunt psychedelic effects through chronic 5-HT₂A downregulation while potentially contributing to serotonin syndrome risk.[20]
- Other serotonergic psychedelics and MDMA: Additive serotonergic burden. At least one hospitalization involved combined βk-2C-B and MDMA use.[3]
- Stimulants (amphetamines, cocaine, methylphenidate): Additive risk of increased heart rate and blood pressure from combined catecholaminergic effects. The Erowid hospital report involved co-administration with amphetamine and MDMA.[3]
- Cannabis: May intensify psychotic symptoms and panic reactions. No βk-2C-B-specific data exist.
- Lithium: Reported to lower seizure threshold when combined with psychedelics. citation needed
- Tricyclic antidepressants: Potential for combined cardiovascular effects via noradrenergic mechanisms. inferred
Contraindications
8 knownNo substance-specific contraindication data exist. The following are inferred from the compound's dual pharmacological class.
Absolute (class-inferred):
- Concurrent MAOI use: Risk of serotonin syndrome.[20]
- Known heart condition (including high blood pressure, irregular heartbeat, coronary artery disease, heart failure): Combined cathinone-type and serotonergic cardiovascular stimulation represents unquantified but significant risk. One unverified report describes cardiac arrest.[3] safety citation needed
- Personal or family history of psychotic disorders: Phenethylamine psychedelics can precipitate acute psychosis.[17]
Relative (class-inferred):
- Seizure disorders: Both cathinones and serotonergic psychedelics have been associated with lowered seizure threshold.[12]
- Liver impairment: If CYP2D6 mediates metabolism (by analogy to 2C-B-FLY[15]), altered liver function could affect clearance. This is speculative.
- Pregnancy and breastfeeding: No reproductive toxicity data exist. Contraindicated by precautionary principle.
- Concurrent serotonergic medication (SSRIs, SNRIs, triptans, tramadol): Risk of serotonin syndrome and unpredictable interactions.[20]
- CYP2D6 poor metabolizer status: Could prolong or intensify effects if CYP2D6 mediates metabolism. This is speculative. inferred
Harm Reduction[edit]
Forms & Identification
βk-2C-B's effective dose range (80–150 mg) demands accurate weighing — a milligram-precision scale is essential, not optional. Because the compound is sold as an unregulated powder with no quality controls, batch-to-batch variation in purity and salt form directly affects potency. Reagent testing confirms the presence of a phenethylamine-type compound but cannot distinguish βk-2C-B from structurally related substances; combined reagent panels improve confidence but do not guarantee identity.
Guidelines
- Test every batch with reagent kits before use. A milligram-precision scale is mandatory at this dose range.
- Start with the low end of the reported range and wait at least 2–3 hours before considering redosing — onset can be slow and unpredictable.
- Clear the entire day. The 8–12 hour duration plus residual stimulation means the experience extends well beyond the primary effects.
- Eat a light meal 2–3 hours before. Hydrate steadily but do not overhydrate.
- Have a sober sitter present, particularly above 130 mg.
- Do not smoke or vaporize this compound. Heating produces toxic pyrolysis products.[4]
- Do not redose to "catch up" — the slow onset and long duration make compounding doses a significant risk.
Set & Setting
The 8–12 hour duration makes environment planning critical — a comfortable, familiar space with no obligations for the full day is the minimum. The pronounced stimulant component means sleep will not be possible for many hours after ingestion. A trusted, sober companion is strongly recommended, especially at doses approaching or exceeding 130 mg where the experience becomes qualitatively more intense and unpredictable.
Aftercare & integration. The extended duration and stimulant component often leave users physically drained. Prioritize sleep, hydration, and nutrition in the 24–48 hours following use. Residual stimulation may make falling asleep difficult — avoid caffeine and screens, and allow the body to wind down naturally.
If the experience was psychologically intense or distressing, journaling and conversation with a trusted person can help process what emerged. Professional psychedelic integration support is appropriate if distressing material persists beyond a few days.
Recovery & Support
βk-2C-B is not considered physically addictive, and compulsive use patterns are rare due to rapid tolerance. If use has become a coping mechanism or is causing disruption in daily life, this reflects a pattern worth examining regardless of the substance's pharmacological dependence profile. Peer support communities, harm reduction organizations, and therapists experienced with substance use can all provide confidential, non-judgmental support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, racing or irregular heartbeat, seizure, loss of consciousness, body temperature hot to the touch, severe confusion, or self-harm behavior all require immediate help. Intense anxiety or a difficult psychological experience, while distressing, is not the same as a medical emergency — reassurance, a calm environment, and patient companionship are usually sufficient.
Immediate steps:
- 1. Move the person to a safe, quiet space.
- 2. Call emergency services if chest pain, seizure, loss of consciousness, or dangerously high body temperature are present.
- 3. Do not restrain the person unless they are in immediate physical danger.
- 4. If the person is unconscious but breathing, place them in the recovery position.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (βk-2C-B / beta-keto 2C-B), approximate dose, time of ingestion, and current symptoms. Be honest about what was taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Legal Status
βk-2C-B is not internationally scheduled under United Nations conventions. Regulatory responses have varied by jurisdiction, with several countries controlling the compound through substance-specific scheduling, blanket psychoactive substance legislation, or structural analog provisions. As of May 2026, βk-2C-B remains unscheduled in most jurisdictions worldwide, though general novel psychoactive substance legislation may apply.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled (federal) | Not explicitly listed in DEA Schedules. The Federal Analogue Act may apply if βk-2C-B is deemed substantially similar to 2C-B (Schedule I), making production, sale, or possession with intent for human consumption a potential federal offense. Interpretation is case-dependent.[7] |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Illegal to produce, supply, or import under blanket psychoactive substance legislation, effective May 26, 2016. Personal possession is not an offense under this Act.[7] |
| Germany | Controlled (NpSG) | Covered under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act), effective November 26, 2016.[7] |
| Switzerland | Controlled (named substance) | Listed as a named substance under Verzeichnis E of Swiss narcotics legislation.[7] |
| Sweden | Narcotic | Classified as a narcotic substance as of April 5, 2019.[7] |
| Canada | Reported Schedule III (CDSA) | Reported as Schedule III under the Controlled Drugs and Substances Act as of October 2016. Canada Gazette Order SOR/2016-73 added 2C-phenethylamine derivatives to Schedule III;[21] however, βk-2C-B is not explicitly named in that Order. Its coverage may depend on class language or a separate order. citation needed |
| Australia | Unconfirmed | Not specifically scheduled under federal or state legislation at the time of research. The cathinone and phenethylamine analogue provisions may apply. citation needed |
Analog and structural considerations
βk-2C-B's classification is complicated by its hybrid structure. In jurisdictions employing analog provisions (such as the US Federal Analogue Act), the compound could be prosecuted as an analog of 2C-B (based on the shared aromatic scaffold) or potentially as an analog of other scheduled cathinones (based on the beta-keto backbone). The applicable designation may differ by jurisdiction and has not been tested in court for this compound.
Frequently asked questions
How long does βk-2C-B last?
Total duration by route of administration — Oral: 8 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for βk-2C-B?
Psychedex publishes a dosage table for βk-2C-B on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with βk-2C-B?
The highest-severity documented interactions for βk-2C-B: MAOIs (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is βk-2C-B addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for βk-2C-B: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DOx series, 2C-x series. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4] ^abcdeTexter KB, Waymach R, Kavanagh PV, O'Brien JE, Talbot B, Brandt SD, Gardner EA (2018) Identification of pyrolysis products of the new psychoactive substance 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) and its iodo analogue bk-2C-I — Drug Testing and Analysis doi:10.1002/dta.2200
- [5] ^Odoardi S, Romolo FS, Strano-Rossi S (2016) A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015 — Forensic science international doi:10.1016/j.forsciint.2016.01.037
- [6] ^Bertol E, Vaiano F, Mari F, Di Milia MG, Bua S, Supuran CT, Carta F (2017) Advances in new psychoactive substances identification: the U.R.I.To.N. Consortium — Journal of Enzyme Inhibition and Medicinal Chemistry doi:10.1080/14756366.2017.1333987
references
- [1]
- [2]
- [3]
- [4] ^abcdeTexter KB, Waymach R, Kavanagh PV, O'Brien JE, Talbot B, Brandt SD, Gardner EA (2018) Identification of pyrolysis products of the new psychoactive substance 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) and its iodo analogue bk-2C-I — Drug Testing and Analysis doi:10.1002/dta.2200
- [5] ^Odoardi S, Romolo FS, Strano-Rossi S (2016) A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015 — Forensic science international doi:10.1016/j.forsciint.2016.01.037
- [6] ^Bertol E, Vaiano F, Mari F, Di Milia MG, Bua S, Supuran CT, Carta F (2017) Advances in new psychoactive substances identification: the U.R.I.To.N. Consortium — Journal of Enzyme Inhibition and Medicinal Chemistry doi:10.1080/14756366.2017.1333987